BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-rusfertide-pdufa-q3-2026-polycythemia-vera@catalyst-calendar.local
DTSTAMP:20260720T200554Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:Takeda/Protagonist rusfertide真性红细胞增多症NDA优先审评窗口
DESCRIPTION:Takeda和Protagonist宣布FDA已受理rusfertide治疗成人真性红细胞增多症NDA并授予优先审评，PDUFA目标在2026年三季度。该事件影响PV治疗中首创hepcidin mimetic机制和血液病罕见病商业化预期。\\nImpact score: 72\\nExpected: FDA决定将验证rusfertide能否成为PV首创机制疗法，并影响PTGX授权价值和Takeda血液病组合。\\nAffected: PTGX(licensor\, unknown\, score 88)\; TAK(licensee\, unknown\, score 62)\; XBI(etf\, mixed\, score 54)\; INCY(peer\, mixed\, score 52)\; NVS(peer\, mixed\, score 48)\\nSources: Takeda rusfertide priority review release: https://www.takeda.com/newsroom/newsreleases/2026/nda-rusfertide/\\nTakeda rusfertide NDA submission: https://www.takeda.com/newsroom/newsreleases/2025/new-drug-application-pv/\\nDrugs.com company release mirror: https://www.drugs.com/nda/rusfertide_260302.html\\nCancerNetwork rusfertide: https://www.cancernetwork.com/view/rusfertide-earns-fda-priority-review-in-polycythemia-vera\\nProtagonist opt-out update: https://www.biospace.com/press-releases/protagonist-exercises-rusfertide-u-s-opt-out-right-under-takeda-collaboration\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-rusfertide-pdufa-q3-2026-polycythemia-vera
CATEGORIES:fda\,US\,FDA\,PDUFA\,hematology\,polycythemia vera\,rusfertide\,hepcidin mimetic
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Takeda/Protagonist rusfertide真性红细胞增多症NDA优先审评窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Takeda/Protagonist rusfertide真性红细胞增多症NDA优先审评窗口
END:VALARM
END:VEVENT
END:VCALENDAR